

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usrpto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/676,734	09/29/2000	Charles Joel Arntzen	P00245US D	1914
75	90 04/30/2003			
Heidi S Nebel Zarley McKee Thomte Voorhees & Sease PLC 801 Grand Avenue Suite 3200			EXAMINER	
			COLLINS, CYNTHIA E	
Des Moines, IA 50309-2721			ART UNIT	PAPER NUMBER
			1638 DATE MAILED: 04/30/2003	12

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Advisory Action	09/676,734	ARNTZEN ET AL.
Advisory Addion	Examiner	Art Unit
	Cynthia Collins	1638
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence address
THE REPLY FILED 09 April 2003 FAILS TO PLACE THE Therefore, further action by the applicant is required to a sinal rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applicated abandonment of this application	ition. A proper reply to a
PERIOD FOR RE	EPLY [check either a) or b)]	
a) The period for reply expires <u>3</u> months from the mailing date		
b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	later than SIX MONTHS from the mailing S FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. IE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The ee have been filed is the date for purposes of determining the period of ee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of 2) as set forth in (b) above, if checked. Any reply received by the Officinely filed, may reduce any earned patent term adjustment. See 37 CFR 1.136(a).	of extension and the corresponding amount the shortened statutory period for reply on the later than three months after the mail	unt of the fee. The appropriate extension originally set in the final Office action; or
<ol> <li>A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFI</li> </ol>		
<ol><li>The proposed amendment(s) will not be entered be</li></ol>	ecause:	
(a) X they raise new issues that would require further	er consideration and/or search (s	see NOTE below);
(b) they raise the issue of new matter (see Note b	pelow);	
(c)  they are not deemed to place the application is issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the
(d)  they present additional claims without canceli	ng a corresponding number of fi	nally rejected claims.
NOTE: See Continuation Sheet.		
3. ☐ Applicant's reply has overcome the following reject	ion(s):	
<ol> <li>Newly proposed or amended claim(s) would canceling the non-allowable claim(s).</li> </ol>	be allowable if submitted in a se	parate, timely filed amendment
5.☐ The a)☐ affidavit, b)☐ exhibit, or c)☐ request for application in condition for allowance because:		dered but does NOT place the
6. The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		·
Claim(s) objected to:		
Claim(s) rejected:		
Claim(s) withdrawn from consideration:		
8. The proposed drawing correction filed on is	a) approved or b) disappo	roved by the Examiner.
9. Note the attached Information Disclosure Statemen	nt(s)( PTO-1449) Paper No(s)	· ,
0. Other:		PHUONG T. BUI 14/24/03 PRIMARY EXAMINER

Application No. 09/676,734

Continuation of 2. NOTE: 2(a) the proposed amendment and the declaration under 37 CFR 1.132 will not be enetered because the proposed amendment raises new issues by the addition of limitations directed to a "mucosal" immune response, which raises new issues that would require further search and consideration under 35 USC 112, 1st paragraph and 35 USC 102 or 103.